Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology

Interleukin-1 in tumor progression, therapy, and prevention

(2021) Cecilia Garlanda et al.   CANCER CELL

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

(2021) L. Paz-Ares et al.   ANNALS OF ONCOLOGY

Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers

(2021) C. Glenn Begley et al.   Science Translational Medicine

Drug repurposing in oncology

(2020) Maria Frantzi et al.   LANCET ONCOLOGY

Estimation of clinical trial success rates and related parameters

(2018) Chi Heem Wong et al.   BIOSTATISTICS

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Drugs that lack single-agent activity: are they worth pursuing in combination?

(2017) Bishal Gyawali et al.   Nature Reviews Clinical Oncology

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

(2014) Ji-Won Kim et al.   Cancer Research and Treatment

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL